Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($0.01), $0.92 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $594.19 million versus the consensus estimate of $588.75 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.